Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Neuromuscular Disorders Channel:
Myasthenia Gravis

Welcome to The Myasthenia Gravis Channel

VJNeurology brings you the latest updates in myasthenia gravis directly from world-leading experts. The Myasthenia Gravis Channel brings you video interviews from international conferences.

Discover key developments in this space, including updates in disease biology, novel treatment strategies, and ongoing clinical trials.

Advancing myasthenia gravis treatment: RAISE trial of zilucoplan 2:27
Advancing myasthenia gravis treatment: RAISE trial of zilucoplan
James F. Howard Jr. • 26 Apr 2023
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis 1:52
Study design for the PREVAIL trial: Phase III study of ALXN1720 in adults with myasthenia gravis
James F. Howard Jr. • 26 Apr 2023
Immunotherapy strategies for autoimmune disorders of the nervous system 1:43
Immunotherapy strategies for autoimmune disorders of the nervous system
Divyanshu Dubey • 12 Apr 2022
Optimization of myasthenia gravis management: knowledge gaps 3:24
Optimization of myasthenia gravis management: knowledge gaps
James F. Howard Jr. • 12 Apr 2022
Complement inhibitor therapy for myasthenia gravis: current and future outlooks 2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr. • 12 Apr 2022
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+ 7:04
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+
James F. Howard Jr. • 12 Apr 2022
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis 2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr. • 12 Apr 2022
Therapeutic targeting of the safety factor in myasthenic syndromes 2:44
Therapeutic targeting of the safety factor in myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Research needs in seronegative myasthenia gravis 1:37
Research needs in seronegative myasthenia gravis
Hakan Cetin • 23 Jun 2021
Safety factor at the neuromuscular junction 3:17
Safety factor at the neuromuscular junction
Hakan Cetin • 23 Jun 2021
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes 2:37
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies 5:46
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies
Angela Vincent • 8 Jun 2021
The expanding treatment landscape for myasthenia gravis 2:11
The expanding treatment landscape for myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
REGAIN study and extension trial of eculizumab in myasthenia gravis 1:34
REGAIN study and extension trial of eculizumab in myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study 1:02
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study
James F. Howard Jr. • 7 Apr 2021
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders 0:45
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders
James F. Howard Jr. • 7 Apr 2021
The content of VJNeurology is intended for healthcare professionals